-DOCSTART- -X- O
Acute -X- _ B-Patient
respiratory -X- _ I-Patient
distress -X- _ I-Patient
syndrome -X- _ I-Patient
( -X- _ I-Patient
ARDS -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
devastating -X- _ O
hypoxemic -X- _ O
respiratory -X- _ O
failure -X- _ O
, -X- _ O
characterized -X- _ O
by -X- _ O
disruption -X- _ O
of -X- _ O
the -X- _ O
alveolar-capillary -X- _ O
membrane -X- _ O
barrier. -X- _ O
Current -X- _ O
management -X- _ O
for -X- _ O
ARDS -X- _ O
remains -X- _ O
supportive -X- _ O
, -X- _ O
including -X- _ O
lung-protective -X- _ O
ventilation -X- _ O
and -X- _ O
a -X- _ O
conservative -X- _ O
fluid -X- _ O
strategy. -X- _ O
Mesenchymal -X- _ O
stem -X- _ O
cells -X- _ O
( -X- _ O
MSCs -X- _ O
) -X- _ O
have -X- _ O
emerged -X- _ O
as -X- _ O
a -X- _ O
potentially -X- _ O
attractive -X- _ O
candidate -X- _ O
for -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
ARDS -X- _ O
through -X- _ O
facilitating -X- _ O
lung -X- _ O
tissue -X- _ O
regeneration -X- _ O
and -X- _ O
repair -X- _ O
by -X- _ O
releasing -X- _ O
paracrine -X- _ O
soluble -X- _ O
factors. -X- _ O
Over -X- _ O
the -X- _ O
last -X- _ O
decade -X- _ O
, -X- _ O
a -X- _ O
variety -X- _ O
of -X- _ O
strategies -X- _ O
have -X- _ O
emerged -X- _ O
to -X- _ O
optimize -X- _ O
MSC-based -X- _ O
therapy. -X- _ O
Among -X- _ O
these -X- _ O
, -X- _ O
the -X- _ O
strategy -X- _ O
using -X- _ O
genetically -X- _ B-Intervention
modified -X- _ I-Intervention
MSCs -X- _ I-Intervention
has -X- _ O
received -X- _ O
increased -X- _ O
attention -X- _ O
recently -X- _ O
due -X- _ B-Outcome
to -X- _ I-Outcome
its -X- _ I-Outcome
distinct -X- _ I-Outcome
advantage -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
conferring -X- _ I-Outcome
incremental -X- _ I-Outcome
migratory -X- _ I-Outcome
capacity -X- _ I-Outcome
and -X- _ I-Outcome
, -X- _ I-Outcome
enhancing -X- _ I-Outcome
the -X- _ I-Outcome
anti-inflammatory -X- _ I-Outcome
, -X- _ I-Outcome
immunomodulatory -X- _ I-Outcome
, -X- _ I-Outcome
angiogenic -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
antifibrotic -X- _ I-Outcome
effects -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
numerous -X- _ I-Outcome
preclinical -X- _ I-Outcome
ARDS -X- _ I-Outcome
models -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
may -X- _ I-Outcome
in -X- _ I-Outcome
turn -X- _ I-Outcome
provide -X- _ I-Outcome
additional -X- _ I-Outcome
benefits -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
management -X- _ I-Outcome
of -X- _ I-Outcome
ARDS. -X- _ I-Outcome
Here -X- _ O
, -X- _ O
we -X- _ O
provide -X- _ O
an -X- _ O
overview -X- _ O
of -X- _ O
recent -X- _ O
studies -X- _ O
testing -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
genetically -X- _ B-Intervention
modified -X- _ I-Intervention
MSCs -X- _ I-Intervention
using -X- _ O
preclinical -X- _ O
models -X- _ O
of -X- _ O
ARDS -X- _ O
. -X- _ O

